Results 201 to 210 of about 20,878 (216)

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Nature Medicine, 2015
Ryan M Young, Stefania Pittaluga, George W Wright   +2 more
exaly  

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Lancet Oncology, The, 2016
Fatih Demirkan, Jiri Mayer, Nancy L Bartlett   +2 more
exaly  

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Journal of Clinical Oncology, 2019
Peter Hillmen, Chris Fegan, Anna Schuh
exaly  

Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase

Circulation, 2020
Ling Xiao, Joe-Elie Salem, Sebastian Clauss   +2 more
exaly  

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Leukemia, 2019
Jan A Burger, Paul M Barr, Tadeusz Robak
exaly  

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Lancet Oncology, The, 2015
Janet Valdez, Georg Aue, Nakhle S Saba
exaly  

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Lancet Oncology, The, 2016
Jeffrey A Jones, Anthony R Mato, Peter Hillmen   +2 more
exaly  

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2013
John C Byrd, Ian W Flinn, Jan A Burger
exaly  

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Lancet Oncology, The, 2014
Jan A Burger, Michael J Keating, William G Wierda   +2 more
exaly  

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

American Journal of Hematology, 2019
Talha Munir, Jennifer R Brown, Susan M O'brien   +2 more
exaly